Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTHAIC: HAIC + Lenvatinib + Toripalimab in Advanced HCC
NCT04044313Phase 2Completed
- Sponsor
- Shiming Biotech
- Start
- Aug 2019
- Primary completion
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, toripalimab in hepatocellular carcinoma (HCC), sponsored by Shiming Biotech. Started Aug 2019; status: completed.
02
Drugs
lenvatinibtoripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04044313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04044313.